{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:08:26Z","timestamp":1791173306299,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.antiviral.2013.10.018","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T15:01:14Z","timestamp":1383836474000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization"],"prefix":"10.1016","volume":"101","author":[{"given":"Maximilian","family":"Deest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Westhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"von Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.10.018_b0005","doi-asserted-by":"crossref","first-page":"e1000978","DOI":"10.1371\/journal.ppat.1000978","article-title":"Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors","volume":"6","author":"Bitzegeio","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.10.018_b0115","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2893.2010.01339.x","article-title":"Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration","volume":"18","author":"Burgel","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.antiviral.2013.10.018_b0015","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/hep.24610","article-title":"The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry","volume":"54","author":"Ciesek","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.10.018_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01548.x","article-title":"Immunosuppression, liver injury and post-transplant HCV recurrence","volume":"19","author":"Ciesek","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.10.018_b0025","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1128\/JVI.00212-11","article-title":"Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles","volume":"85","author":"Ciesek","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.10.018_b0030","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1053\/he.2000.5762","article-title":"Natural history of hepatitis C: its impact on clinical management","volume":"31","author":"Di Bisceglie","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.10.018_b0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.10.018_b0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nbt.1604","article-title":"Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system","volume":"28","author":"Jones","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2013.10.018_b0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2013.10.018_b0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.immunol.16.1.89","article-title":"CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system","volume":"16","author":"Levy","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2013.10.018_b0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2013.10.018_b0060","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo","volume":"48","author":"Meuleman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.10.018_b0065","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.10.018_b0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2013.10.018_b0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2012.09.044","article-title":"Barriers of hepatitis C virus interspecies transmission","volume":"435","author":"Sandmann","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.10.018_b0080","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2013.10.018_b0085","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2013.10.018_b0090","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.10.018_b0095","first-page":"237","article-title":"Arrest all accessories-inhibition of hepatitis C virus by compounds that target host factors","volume":"12","author":"von Hahn","year":"2011","journal-title":"Discov. Med."},{"issue":"439\u2013447","key":"10.1016\/j.antiviral.2013.10.018_b0100","first-page":"e431","article-title":"Hepatocytes that express variants of cyclophilin a are resistant to HCV infection and replication","volume":"143","author":"von Hahn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.10.018_b0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/egh.09.74","article-title":"Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches","volume":"4","author":"von Hahn","year":"2010","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.10.018_b0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J. Gen. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:25:58Z","timestamp":1759062358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":22,"alternative-id":["S0166354213003215"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.10.018","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}